share_log

新銳醫藥：內幕消息－虧損大幅減少

NEW RAY MEDIC: INSIDE INFORMATION - SUBSTANTIAL REDUCTION IN LOSS

香港交易所 ·  Mar 15 09:19
Summary by Moomoo AI
新銳醫藥國際控股有限公司（新锐医药）預告，截至2023年12月31日的財政年度，集團淨虧損將不超過3000萬港元，較2022年的7790萬港元大幅減少。這一改善主要歸因於該年度未錄得股份為基礎付款開支，以及存貨減值虧損額的顯著降低。公司指出，2023年度的財務數據尚未經審核，且未經核數師審閱或審核，最終數據可能會有所調整。公司將於2024年3月底前公布完整的財務業績。
新銳醫藥國際控股有限公司（新锐医药）預告，截至2023年12月31日的財政年度，集團淨虧損將不超過3000萬港元，較2022年的7790萬港元大幅減少。這一改善主要歸因於該年度未錄得股份為基礎付款開支，以及存貨減值虧損額的顯著降低。公司指出，2023年度的財務數據尚未經審核，且未經核數師審閱或審核，最終數據可能會有所調整。公司將於2024年3月底前公布完整的財務業績。
NEW SHARP PHARMACEUTICALS INTERNATIONAL HOLDINGS LIMITED (NEW SHARP PHARMACEUTICALS) FORECASTS THAT THE GROUP'S NET LOSS FOR THE FISCAL YEAR TO DECEMBER 31, 2023 WILL NOT EXCEED HKD3000 MILLION, A SIGNIFICANT DECREASE FROM HK$7790 MILLION IN 2022. The improvement was primarily attributable to unrecognized share-based payment expenses for the year, as well as a significant reduction in inventory impairment losses. The company notes that the financial data for 2023 has not yet been audited and the final data may be adjusted without review or review by auditors. The company will publish full financial results by the end of March 2024.
NEW SHARP PHARMACEUTICALS INTERNATIONAL HOLDINGS LIMITED (NEW SHARP PHARMACEUTICALS) FORECASTS THAT THE GROUP'S NET LOSS FOR THE FISCAL YEAR TO DECEMBER 31, 2023 WILL NOT EXCEED HKD3000 MILLION, A SIGNIFICANT DECREASE FROM HK$7790 MILLION IN 2022. The improvement was primarily attributable to unrecognized share-based payment expenses for the year, as well as a significant reduction in inventory impairment losses. The company notes that the financial data for 2023 has not yet been audited and the final data may be adjusted without review or review by auditors. The company will publish full financial results by the end of March 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more